VolitionRx Limited, a multi-national epigenetics company, announced its financial results for the first quarter ended March 31, 2025. The company reported a revenue of approximately $0.25 million in Q1 2025, marking a 44% increase compared to the same period in the previous year. Net cash used in operating activities averaged $1.4 million per month, which is almost 50% lower than during the first quarter of 2024. The company had cash and cash equivalents totaling approximately $2.6 million as of March 31, 2025, compared to $3.3 million at the end of December 2024. During the first quarter, VolitionRx received funding receipts totaling $4.3 million, with approximately $1.8 million coming from non-dilutive funding and the remainder from capital markets. The company also achieved a significant commercial milestone by recording its first revenue from sales of its CE-marked Nu.Q® NETs automated product in Europe. VolitionRx is focusing on commercializing its Nu.Q® platform in the human diagnostics market and is in confidential discussions with more than ten companies, aiming to secure multiple licensing agreements this year. The company is also leveraging its granted CE mark for NETs related diseases in the EU.